CV9201 is a cancer immunotherapy based on RNActive® technology, encoding five antigens associated with NSCLC: New York esophageal squamous cell carcinoma-1 (NY-ESO-1), melanoma antigen family C1 and C2 (MAGE-C1 and MAGE-C2), survivin, and trophoblast glycoprotein (5T4) [22]. Here, TPBG is linked to esophageal squamous cell carcinoma.